Skip to content
Catalyst

3-hydroxybutyric acidWhat was measured

Measured, with no finding

535 endpoints

Show what was measuredHide what was measured
  • average 150-kJ time-trial power output

    decreases, p = 0.029

    Average time-trial power output was ∼7% lower (-16 W, p = 0.029) in the ketone condition

    PMID 28750585 · one of two readings recorded this

  • average power output in a 150-kJ cycling time-trial

    decreases, about 7% lower (-16 W), p = 0.029

    Not recorded as a finding: endpoint_near_miss: mean-power-output requires a fixed-duration maximal effort and time-trial-performance requires fixed-distance completion time, while this is power over fixed work

    Average time-trial power output was ∼7% lower (-16 W, p = 0.029) in the ketone condition.

    PMID 28750585 · one of two readings recorded this

  • average power output over a 150-kJ cycling time-trial

    decreases, about 7% lower (-16 W), p = 0.029

    Not recorded as a finding: No node fits: time-trial-performance is a fixed-distance completion time and mean-power-output is a fixed-duration Wingate-type effort; this is mean power over a fixed-work trial

    Average time-trial power output was ∼7% lower (-16 W, p = 0.029) in the ketone condition.

    PMID 28750585 · one of two readings recorded this

  • plasma β-OHB

    increases, p = 0.05

    Plasma β-OHB was elevated from baseline and throughout the entire protocol in the ketone condition (p < 0.05)

    PMID 28750585 · one of two readings recorded this

  • respiratory exchange ratio at 30% and 60% ventilatory threshold, indirect calorimetry

    decreases

    Not recorded as a finding: No outcome node for respiratory exchange ratio during exercise

    RER was lower at 30% and 60% VT in the ketone compared with control condition.

    PMID 28750585 · both readings recorded this

  • respiratory exchange ratio

    decreases

    RER was lower at 30% and 60% VT in the ketone compared with control condition

    PMID 28750585 · one of two readings recorded this

  • respiratory exchange ratio

    decreases

    RER was lower at 30% and 60% VT in the ketone compared with control condition

    PMID 28750585 · one of two readings recorded this

  • total fat oxidation

    increases, p = 0.05

    Total fat oxidation was greater in the ketone versus control (p = 0.05)

    PMID 28750585 · one of two readings recorded this

  • total antioxidant capacity

    increases, p = 0.028

    Liver total antioxidant capacity levels were significantly higher in KD versus SC rats (p = 0.028), but not KD versus SC + KS rats (p = 0.216; Figure 8d)

    PMID 28914762 · one of two readings recorded this

  • total antioxidant capacity

    no effect, p = 0.275

    was not different between the KD and SC groups (p = 0.275) or SC and SC + KS groups (p = 0.366)

    PMID 28914762 · one of two readings recorded this

  • total antioxidant capacity

    no effect, p = 0.366

    was not different between the KD and SC groups (p = 0.275) or SC and SC + KS groups (p = 0.366)

    PMID 28914762 · one of two readings recorded this

  • total antioxidant capacity

    no effect, p = 0.216

    Liver total antioxidant capacity levels were significantly higher in KD versus SC rats (p = 0.028), but not KD versus SC + KS rats (p = 0.216; Figure 8d)

    PMID 28914762 · one of two readings recorded this

  • total antioxidant capacity

    decreases, p = 0.019

    gastrocnemius antioxidant capacity was significantly lower in KD versus SC + KS rats (p = 0.019)

    PMID 28914762 · one of two readings recorded this

  • total antioxidant capacity

    no effect, p = 0.146

    Gastrocnemius total antioxidant capacity levels were not different between groups (ANOVA p = 0.146; Figure 8d)

    PMID 28914762 · one of two readings recorded this

  • total antioxidant capacity

    modulates, p = 0.025

    Gastrocnemius antioxidant capacity was significantly different between groups (ANOVA p = 0.025; Figure 2d)

    PMID 28914762 · one of two readings recorded this

  • 4-HNE

    no effect, p = 0.725

    gastrocnemius 4-HNE (ANOVA p = 0.725) and protein carbonyl levels (ANOVA p = 0.504) were not differentially expressed groups

    PMID 28914762 · one of two readings recorded this

  • change in body mass

    decreases, p = 0.001

    change in body mass at day 3 was significantly lower in KD versus SC and SC + KS rats (p < 0.001 and p < 0.001, respectively)

    PMID 28914762 · one of two readings recorded this

  • change in body mass

    decreases, p = 0.01

    this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)

    PMID 28914762 · one of two readings recorded this

  • change in body mass

    decreases, p = 0.036

    this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)

    PMID 28914762 · one of two readings recorded this

  • change in body mass

    decreases, p = 0.001

    change in body mass at day 3 was significantly lower in KD versus SC and SC + KS rats (p < 0.001 and p < 0.001, respectively)

    PMID 28914762 · one of two readings recorded this

  • change in body mass

    decreases, p = 0.002

    this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)

    PMID 28914762 · one of two readings recorded this

  • change in body mass

    decreases, p = 0.001

    this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)

    PMID 28914762 · one of two readings recorded this

  • citrate synthase activity

    no effect, p = 0.386

    Citrate synthase activity levels in the brain (ANOVA p = 0.386) and liver (ANOVA p = 0.548) were similar between groups

    PMID 28914762 · one of two readings recorded this

  • citrate synthase activity

    decreases, p = 0.009

    values were lower in KD versus SC + KS (p < 0.001) and SC (p = 0.009) rats

    PMID 28914762 · one of two readings recorded this

  • citrate synthase activity

    decreases, p = 0.001

    values were lower in KD versus SC + KS (p < 0.001) and SC (p = 0.009) rats

    PMID 28914762 · one of two readings recorded this

  • feed efficiency

    decreases, p = 0.001

    KD rats presented significantly feed efficiency values compared to SC + KS rats (p < 0.001) and SC rats (p < 0.001)

    PMID 28914762 · one of two readings recorded this

  • feed efficiency

    unclear, p = 0.07

    KD rats presented significantly lower values compared to SC + KS rats (p < 0.001) and differences between KD and SC rats approached significance (p = 0.070)

    PMID 28914762 · one of two readings recorded this

  • feed efficiency

    decreases, p = 0.001

    KD rats presented significantly feed efficiency values compared to SC + KS rats (p < 0.001) and SC rats (p < 0.001)

    PMID 28914762 · one of two readings recorded this

  • feed efficiency

    decreases, p = 0.001

    KD rats presented significantly lower values compared to SC + KS rats (p < 0.001) and differences between KD and SC rats approached significance (p = 0.070)

    PMID 28914762 · one of two readings recorded this

  • liver protein carbonyls by Oxyblot Western blot, Fisher 344 rats fed standard chow plus sodium DL-beta-hydroxybutyrate in drinking water for 8 months against standard chow alone

    increases, protein carbonyls greater in SC + KS than in SC, p = 0.034, p = 0.034

    Not recorded as a finding: this platform holds no node for the endpoint

    Liver 4-HNE levels were not differentially expressed between groups (ANOVA p = 0.684), although liver protein carbonyls were greater in the SC + KS versus SC (p = 0.034) and KD (p = 0.001) groups.

    PMID 28914762 · one of two readings recorded this

  • mitochondrial GSH

    no effect, p = 0.191

    Brain mitochondrial GSSG (ANOVA p = 0.294), GSH (ANOVA p = 0.191) and total glutathione (ANOVA p = 0.200) were not differentially expressed between groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial GSH

    increases, p = 0.001

    GSH levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.004) groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial GSH

    increases, p = 0.004

    GSH levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.004) groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial GSSG

    no effect, p = 0.294

    Brain mitochondrial GSSG (ANOVA p = 0.294), GSH (ANOVA p = 0.191) and total glutathione (ANOVA p = 0.200) were not differentially expressed between groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial GSSG

    increases, p = 0.018

    GSSG levels were greater in SC-fed versus KD-fed rats (p = 0.018) and trended higher in SC-fed versus SC + KS-fed rats (p = 0.063)

    PMID 28914762 · one of two readings recorded this

  • mitochondrial GSSG

    unclear, p = 0.063

    GSSG levels were greater in SC-fed versus KD-fed rats (p = 0.018) and trended higher in SC-fed versus SC + KS-fed rats (p = 0.063)

    PMID 28914762 · one of two readings recorded this

  • mitochondrial ROS production

    no effect, p = 0.162

    Mitochondrial ROS production in the brain (ANOVA p = 0.162) and liver (ANOVA p = 0.222) were not different between groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial ROS production

    increases, p = 0.014

    ROS values were significantly higher in KD rats versus the SC (p = 0.014) and SC + KS groups (p = 0.015)

    PMID 28914762 · one of two readings recorded this

  • mitochondrial ROS production

    increases, p = 0.015

    ROS values were significantly higher in KD rats versus the SC (p = 0.014) and SC + KS groups (p = 0.015)

    PMID 28914762 · one of two readings recorded this

  • mitochondrial total glutathione

    no effect, p = 0.2

    Brain mitochondrial GSSG (ANOVA p = 0.294), GSH (ANOVA p = 0.191) and total glutathione (ANOVA p = 0.200) were not differentially expressed between groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial total glutathione

    increases, p = 0.001

    total glutathione levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.005) groups

    PMID 28914762 · one of two readings recorded this

  • mitochondrial total glutathione

    increases, p = 0.005

    total glutathione levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.005) groups

    PMID 28914762 · one of two readings recorded this

  • oxidative stress-related mRNAs (Gclm, Gclc, Gsr, Gpx1, Cat, Sod2)

    no effect, p = 0.05

    Oxidative stress-related genes (i.e., Gclm, Gclc, Gsr, Gpx1, Cat or Sod2) were not differentially expressed in the gastrocnemius, brain or liver (all ANOVA p > 0.05; Figure 2a–c)

    PMID 28914762 · one of two readings recorded this

  • oxidative stress-related mRNAs (Gclm, Gclc, Gsr, Gpx1, Cat, Sod2)

    no effect, p = 0.05

    Oxidative stress-related genes (i.e., Gclm, Gclc, Gsr, Gpx1, Cat or Sod2) were not differentially expressed in the gastrocnemius, brain or liver (all ANOVA p > 0.05; Figure 2a–c)

    PMID 28914762 · one of two readings recorded this

  • oxidative stress-related mRNAs (Gclm, Gclc, Gsr, Gpx1, Cat, Sod2)

    no effect, p = 0.05

    Oxidative stress-related genes (i.e., Gclm, Gclc, Gsr, Gpx1, Cat or Sod2) were not differentially expressed in the gastrocnemius, brain or liver (all ANOVA p > 0.05; Figure 2a–c)

    PMID 28914762 · one of two readings recorded this

  • protein carbonyls

    no effect, p = 0.504

    gastrocnemius 4-HNE (ANOVA p = 0.725) and protein carbonyl levels (ANOVA p = 0.504) were not differentially expressed groups

    PMID 28914762 · one of two readings recorded this

  • protein carbonyls

    increases, p = 0.034

    liver protein carbonyls were greater in the SC + KS versus SC (p = 0.034) and KD (p = 0.001) groups

    PMID 28914762 · one of two readings recorded this

  • protein carbonyls

    increases, p = 0.001

    liver protein carbonyls were greater in the SC + KS versus SC (p = 0.034) and KD (p = 0.001) groups

    PMID 28914762 · one of two readings recorded this

  • protein expression of Cat

    no effect, p = 0.393

    Gastrocnemius protein expression levels of Cat (ANOVA p = 0.393), Gpx (ANOVA p = 0.702) and Sod2 (ANOVA p = 0.925) were not differentially expressed between groups

    PMID 28914762 · one of two readings recorded this

  • protein expression of Gpx

    no effect, p = 0.702

    Gastrocnemius protein expression levels of Cat (ANOVA p = 0.393), Gpx (ANOVA p = 0.702) and Sod2 (ANOVA p = 0.925) were not differentially expressed between groups

    PMID 28914762 · one of two readings recorded this

  • protein expression of Gpx

    increases, p = 0.004

    Liver protein expression levels of Gpx were greater in the KD versus the SC group (p = 0.004) and high levels approached significance in the KD versus the SC + KS group (p = 0.068)

    PMID 28914762 · one of two readings recorded this

  • protein expression of Gpx

    unclear, p = 0.068

    Liver protein expression levels of Gpx were greater in the KD versus the SC group (p = 0.004) and high levels approached significance in the KD versus the SC + KS group (p = 0.068)

    PMID 28914762 · one of two readings recorded this

  • protein expression of Sod2

    no effect, p = 0.925

    Gastrocnemius protein expression levels of Cat (ANOVA p = 0.393), Gpx (ANOVA p = 0.702) and Sod2 (ANOVA p = 0.925) were not differentially expressed between groups

    PMID 28914762 · one of two readings recorded this

  • pyruvate-malate respiratory control ratio

    no effect, p = 0.582

    Brain pyruvate-malate state 3 (ANOVA p = 0.706), pyruvate-malate state 4 (ANOVA p = 0.500) and pyruvate-malate RCR values (ANOVA p = 0.582; Figure 10a) were not different between groups

    PMID 28914762 · one of two readings recorded this

  • pyruvate-malate respiratory control ratio

    decreases, p = 0.03

    values were significantly lower in KD versus SC rats (p = 0.030) and SC + KS versus SC rats (p = 0.035)

    PMID 28914762 · one of two readings recorded this

  • pyruvate-malate respiratory control ratio

    decreases, p = 0.035

    values were significantly lower in KD versus SC rats (p = 0.030) and SC + KS versus SC rats (p = 0.035)

    PMID 28914762 · one of two readings recorded this

  • pyruvate-malate state 3 respiration

    no effect, p = 0.706

    Brain pyruvate-malate state 3 (ANOVA p = 0.706), pyruvate-malate state 4 (ANOVA p = 0.500) and pyruvate-malate RCR values (ANOVA p = 0.582; Figure 10a) were not different between groups

    PMID 28914762 · one of two readings recorded this

  • pyruvate-malate state 3 respiration

    unclear, p = 0.064

    lower values in KD versus SC rats approached significance (p = 0.064)

    PMID 28914762 · one of two readings recorded this

  • pyruvate-malate state 4 respiration

    no effect, p = 0.119

    Gastrocnemius pyruvate-malate state 4 was not different between groups (p = 0.119; Figure 9b)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance, main group effect

    increases, p = 0.001

    rotarod performance was significantly higher in KD rats versus SC (p = 0.001) and SC + KS rats (p = 0.005)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance, main group effect

    increases, p = 0.005

    rotarod performance was significantly higher in KD rats versus SC (p = 0.001) and SC + KS rats (p = 0.005)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance over time within KD group

    decreases, p = 0.006

    within the KD group there was a significant time effect (p = 0.001) whereby values at 6 months (p = 0.006) and 8 months (p = 0.021) were significantly lower than 2 months values

    PMID 28914762 · one of two readings recorded this

  • rotarod performance over time within KD group

    decreases, p = 0.021

    within the KD group there was a significant time effect (p = 0.001) whereby values at 6 months (p = 0.006) and 8 months (p = 0.021) were significantly lower than 2 months values

    PMID 28914762 · one of two readings recorded this

  • rotarod performance over time within KD group

    decreases, p = 0.001

    within the KD group there was a significant time effect (p = 0.001) whereby values at 6 months (p = 0.006) and 8 months (p = 0.021) were significantly lower than 2 months values

    PMID 28914762 · one of two readings recorded this

  • rotarod performance over time within SC group

    no effect, p = 0.531

    there was no time effect within the SC (p = 0.531) and SC + KS groups (p = 0.382)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance over time within SC + KS group

    no effect, p = 0.382

    there was no time effect within the SC (p = 0.531) and SC + KS groups (p = 0.382)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance

    increases, p = 0.001

    at 2 months, performance was significantly higher in the KD versus the SC (p < 0.001) and SC + KS groups (p = 0.009)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance

    increases, p = 0.017

    at 4 months, performance was significantly higher in the KD versus the SC (p = 0.017) group, and values between the KD versus SC + KS group approached significance (p = 0.060)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance

    increases, p = 0.008

    at 8 months, performance was significantly higher in the KD versus the SC (p = 0.008) and SC + KS groups (p = 0.049)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance

    increases, p = 0.009

    at 2 months, performance was significantly higher in the KD versus the SC (p < 0.001) and SC + KS groups (p = 0.009)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance

    unclear, p = 0.06

    at 4 months, performance was significantly higher in the KD versus the SC (p = 0.017) group, and values between the KD versus SC + KS group approached significance (p = 0.060)

    PMID 28914762 · one of two readings recorded this

  • rotarod performance

    increases, p = 0.049

    at 8 months, performance was significantly higher in the KD versus the SC (p = 0.008) and SC + KS groups (p = 0.049)

    PMID 28914762 · one of two readings recorded this

  • serum BHB

    increases, p = 0.001

    serum BHB values were higher in KD versus SC rats (p < 0.001) and SC + KS rats (p < 0.001)

    PMID 28914762 · one of two readings recorded this

  • serum BHB

    no effect, p = 0.14

    serum BHB levels were higher in KD versus SC + KS rats (p = 0.034), but not different between KD and SC rats (p = 0.140)

    PMID 28914762 · one of two readings recorded this

  • serum BHB

    increases, p = 0.001

    serum BHB values were higher in KD versus SC rats (p < 0.001) and SC + KS rats (p < 0.001)

    PMID 28914762 · one of two readings recorded this

  • serum BHB

    increases, p = 0.034

    serum BHB levels were higher in KD versus SC + KS rats (p = 0.034), but not different between KD and SC rats (p = 0.140)

    PMID 28914762 · one of two readings recorded this

  • sodium beta-hydroxybutyrate intake through drinking water

    SC + KS rats consumed an average of 0.85 ± 0.03 g/day of sodium beta-hydroxybutyrate over the 1-week intervention through their drinking water

    PMID 28914762 · one of two readings recorded this

  • sodium beta-hydroxybutyrate salt intake through drinking water

    SC + KS rats consumed an average of 0.21 ± 0.02 g/day of sodium beta-hydroxybutyrate salts through their drinking water over the 8 months intervention

    PMID 28914762 · one of two readings recorded this

  • succinate respiratory control ratio

    no effect, p = 0.582

    Gastrocnemius succinate state 3 (ANOVA p = 0.706; Figure 9d), succinate state 4 (ANOVA p = 0.500; Figure 9e) and succinate RCR values (ANOVA p = 0.582; Figure 9f) were not different between groups

    PMID 28914762 · one of two readings recorded this

  • succinate state 3 respiration

    no effect, p = 0.706

    Gastrocnemius succinate state 3 (ANOVA p = 0.706; Figure 9d), succinate state 4 (ANOVA p = 0.500; Figure 9e) and succinate RCR values (ANOVA p = 0.582; Figure 9f) were not different between groups

    PMID 28914762 · one of two readings recorded this

  • succinate state 4 respiration

    no effect, p = 0.5

    Gastrocnemius succinate state 3 (ANOVA p = 0.706; Figure 9d), succinate state 4 (ANOVA p = 0.500; Figure 9e) and succinate RCR values (ANOVA p = 0.582; Figure 9f) were not different between groups

    PMID 28914762 · one of two readings recorded this

  • weekly body mass

    decreases, p = 0.05

    KD rats weighed less than SC and SC + KS rats from 10 weeks to 30 weeks (p < 0.05 at all time points; Figure 3a)

    PMID 28914762 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.0001

    compared to both control (p < 0.0001 for KD, KS and KE) and baseline (p < 0.0001 for KD and KS; p = 0.03 for KE

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.0001

    compared to both control (p < 0.0001 for both KE and KS) and baseline (p < 0.0001 for both KE and KS) levels

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.02

    Significantly increased blood βHB levels were also detected in KE and KS supplemented mice, compared to their baseline levels (KE: p = 0.02; KS: p = 0.04)

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.03

    compared to both control (p < 0.0001 for KD, KS and KE) and baseline (p < 0.0001 for KD and KS; p = 0.03 for KE

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.04

    Significantly increased blood βHB levels were also detected in KE and KS supplemented mice, compared to their baseline levels (KE: p = 0.02; KS: p = 0.04)

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0001

    compared to both control (p < 0.0001 for KD, KS and KE) and baseline (p < 0.0001 for KD and KS; p = 0.03 for KE

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    unclear, p = 0.07

    The mice fed KD, or SD with KE, or KS exhibited elevated (KD: p = 0.07) or significantly increased (KE: p = 0.0117; KS: p = 0.0169) blood levels of βHB relative to control mice

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0001

    compared to both control (p < 0.0001 for both KE and KS) and baseline (p < 0.0001 for both KE and KS) levels

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0117

    The mice fed KD, or SD with KE, or KS exhibited elevated (KD: p = 0.07) or significantly increased (KE: p = 0.0117; KS: p = 0.0169) blood levels of βHB relative to control mice

    PMID 30021521 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0169

    The mice fed KD, or SD with KE, or KS exhibited elevated (KD: p = 0.07) or significantly increased (KE: p = 0.0117; KS: p = 0.0169) blood levels of βHB relative to control mice

    PMID 30021521 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases, p = 0.27

    when the group means were considered (R2 = 0.4531, p = 0.27)

    PMID 30021521 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases, p = 0.096

    positively correlated, but not significantly when the group means were considered (R2 = 0.8164, p = 0.096)

    PMID 30021521 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases, p = 0.0001

    when individual data points (R2 = 0.4481, p < 0.0001, Fig. 1c)

    PMID 30021521 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases, p = 0.04

    or the group means were considered (R2 = 0.995, p = 0.04)

    PMID 30021521 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases, p = 0.0002

    when individual data points (R2 = 0.4862, p = 0.0002, Fig. 3c)

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility, seconds from chamber closure, in Sprague-Dawley rats, G1D mice and WAG/Rij rats

    increases

    Not recorded as a finding: no outcome node for anaesthetic induction latency

    Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively), relative to control mice fed a SD.

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility (time until immobility after chamber closure) in rats and G1D mice

    increases

    Not recorded as a finding: no outcome node for anaesthetic induction latency

    Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively), relative to control mice fed a SD.

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.0003

    Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively)

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.0001

    Treatment with KD and SD with KS caused a significant increase in the number of seconds required before anesthetic induction (the time until immobility) (p < 0.0001, and p = 0.0337, respectively)

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.0003

    Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively)

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.0001

    SD with KE or KS significantly increased the time required before anesthetic induction (p < 0.0001, p = 0.02, respectively), compared to controls (SD) in WAG/Rij rats

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.0136

    Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively)

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.0337

    Treatment with KD and SD with KS caused a significant increase in the number of seconds required before anesthetic induction (the time until immobility) (p < 0.0001, and p = 0.0337, respectively)

    PMID 30021521 · one of two readings recorded this

  • latency to isoflurane-induced immobility

    increases, p = 0.02

    SD with KE or KS significantly increased the time required before anesthetic induction (p < 0.0001, p = 0.02, respectively), compared to controls (SD) in WAG/Rij rats

    PMID 30021521 · one of two readings recorded this

  • blood acetoacetate fold versus control

    increases

    In groups treated with KE, KE+MCT and KE/2 the AcAc levels were higher than control (water) by factors of 16, 15, and 14, respectively

    PMID 30604923 · one of two readings recorded this

  • blood acetoacetate fold versus control

    increases

    In groups treated with KE, KE+MCT and KE/2 the AcAc levels were higher than control (water) by factors of 16, 15, and 14, respectively

    PMID 30604923 · one of two readings recorded this

  • blood acetoacetate fold versus control

    increases

    In groups treated with KE, KE+MCT and KE/2 the AcAc levels were higher than control (water) by factors of 16, 15, and 14, respectively

    PMID 30604923 · one of two readings recorded this

  • blood acetoacetate

    increases, p = 0.0001

    AcAc was significantly higher in all treatment groups compared to control (P < 0.0001; Fig. 3C)

    PMID 30604923 · one of two readings recorded this

  • blood D-beta-hydroxybutyrate after gavage, Precision Xtra meter (does not detect L-beta-hydroxybutyrate), measured immediately after removal from the hyperbaric chamber; and latency to CNS oxygen toxicity seizure at 5 ATA

    increases, about two times higher blood D-beta-hydroxybutyrate than control in the KS+MCT group, p = 0.0006

    Not recorded as a finding: the intervention held more than the compound

    The KE/2 group (P = 0.0012) had higher βHB level then the control by a factor of approximately three, while it was about two times higher in the KS+MCT (P = 0.0006) group.

    PMID 30604923 · one of two readings recorded this

  • blood D-beta-hydroxybutyrate

    increases, p = 0.0012

    The KE/2 group (P = 0.0012) had higher βHB level then the control by a factor of approximately three

    PMID 30604923 · one of two readings recorded this

  • blood D-beta-hydroxybutyrate

    increases, p = 0.0002

    Treatment with KE (P < 0.0001) and KE+MCT (P = 0.0002) resulted in higher βHB levels

    PMID 30604923 · one of two readings recorded this

  • blood D-beta-hydroxybutyrate

    increases, p = 0.0001

    Treatment with KE (P < 0.0001) and KE+MCT (P = 0.0002) resulted in higher βHB levels

    PMID 30604923 · one of two readings recorded this

  • blood D-beta-hydroxybutyrate

    increases, p = 0.0006

    while it was about two times higher in the KS+MCT (P = 0.0006) group

    PMID 30604923 · one of two readings recorded this

  • blood glucose

    no effect

    Blood glucose and body weight were not significantly different between the treatment groups and control

    PMID 30604923 · one of two readings recorded this

  • body weight

    no effect

    Blood glucose and body weight were not significantly different between the treatment groups and control

    PMID 30604923 · one of two readings recorded this

  • correlation of blood D-beta-hydroxybutyrate with latency to seizure

    increases

    There was a strong positive correlation between βHB levels and LS when all treatment groups were considered

    PMID 30604923 · one of two readings recorded this

  • delay to seizure relative to control

    increases

    The KE/2 group delayed seizure by 55%

    PMID 30604923 · one of two readings recorded this

  • delay to seizure relative to control

    increases

    LS = 219%

    PMID 30604923 · one of two readings recorded this

  • delay to seizure relative to control

    increases

    the KE group experienced a delay to seizure of 179%, as compared to the control group

    PMID 30604923 · one of two readings recorded this

  • latency to seizure at 5 ATA

    increases, p = 0.023

    LS was significantly delayed in the KE (P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028) groups

    PMID 30604923 · one of two readings recorded this

  • latency to seizure at 5 ATA

    increases, p = 0.049

    was documented in KE+MCT group (P = 0.049; Fig. 1A)

    PMID 30604923 · one of two readings recorded this

  • latency to seizure at 5 ATA

    increases, p = 0.028

    LS was significantly delayed in the KE (P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028) groups

    PMID 30604923 · one of two readings recorded this

  • latency to seizure at 5 ATA

    increases, p = 0.0003

    LS was significantly delayed in the KE (P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028) groups

    PMID 30604923 · one of two readings recorded this

  • latency to seizure at 5 ATA

    unclear

    The KS+MCT treatment group showed a trend for delayed

    PMID 30604923 · one of two readings recorded this

  • latency to seizure in young versus aged rats

    no effect, p = 0.07

    The LS in young and aged rats was not significantly different (P = 0.07)

    PMID 30604923 · one of two readings recorded this

  • latency to seizure, KE versus KE/2

    increases, p = 0.011

    LS was also significantly different between KE and KE/2 groups (P = 0.011)

    PMID 30604923 · one of two readings recorded this

  • latency to tonic-clonic seizure under hyperbaric oxygen at 5 ATA, and seizure severity score 0 to 3, 18-month-old Sprague-Dawley rats

    no effect, KS+MCT showed a trend for delayed seizure latency, not significant against water control, n = 7

    Not recorded as a finding: the intervention held more than the compound

    The KS+MCT treatment group showed a trend for delayed CNS‐OT, but was not significant when compared to control (water).

    PMID 30604923 · one of two readings recorded this

  • seizure severity score

    unclear

    showed a trend towards less severity without significance in KE/2, and KE+MCT groups

    PMID 30604923 · one of two readings recorded this

  • seizure severity score

    unclear

    showed a trend towards less severity without significance in KE/2, and KE+MCT groups

    PMID 30604923 · one of two readings recorded this

  • seizure severity score

    decreases, p = 0.015

    the severity of seizures, determined by the blinded experimenter, was significantly less in KE (P = 0.015)

    PMID 30604923 · one of two readings recorded this

  • caspase-1 activation in LPS-stimulated whole blood, 30 min after dosing

    increases, p = 0.012

    Not recorded as a finding: no outcome node for stimulated caspase-1 activation; recorded in mechanism_claims

    Caspase-1 activation increases after ketone salt (Study 1: condition × time interaction, p = 0.012) and monoester supplementation (Study 2: condition × time interaction, p = 0.016) compared to placebo.

    PMID 30912285 · one of two readings recorded this

  • caspase-1 activation

    increases, p = 0.016, n = 18

    monoester supplementation (Study 2: condition × time interaction, p = 0.016) compared to placebo

    PMID 30912285 · one of two readings recorded this

  • caspase-1 activation

    increases, p = 0.012, n = 10

    Caspase-1 activation increases after ketone salt (Study 1: condition × time interaction, p = 0.012)

    PMID 30912285 · one of two readings recorded this

  • IL-1β secretion

    increases, p = 0.024, n = 18

    IL-1β secretion increases (main effect of condition, p = 0.024; Study 2)

    PMID 30912285 · one of two readings recorded this

  • IL-1beta secretion from LPS-stimulated whole blood after ketone supplementation, ex vivo

    increases, p = 0.024

    Not recorded as a finding: Stated for Study 2 (ketone monoester) only, which is not this subject; no node for stimulated IL-1beta

    IL-1β secretion increases (main effect of condition, p = 0.024; Study 2) while IL1B and NLRP3 mRNA remain unchanged.

    PMID 30912285 · one of two readings recorded this

  • IL1B mRNA

    no effect

    IL-1β secretion increases (main effect of condition, p = 0.024; Study 2) while IL1B and NLRP3 mRNA remain unchanged

    PMID 30912285 · one of two readings recorded this

  • NLRP3 mRNA

    no effect

    IL-1β secretion increases (main effect of condition, p = 0.024; Study 2) while IL1B and NLRP3 mRNA remain unchanged

    PMID 30912285 · one of two readings recorded this

  • gastrointestinal symptom load, 0-8 Likert symptom severity, ketone salt drinks at high versus low dose and versus ketone monoester

    increases, 13.8 ± 4.3 vs. 2.0 ± 1.0

    Not recorded as a finding: the comparison was against another active treatment

    High-dose KS drinks caused greater total-visit symptom load than low-dose KS drinks (13.8 ± 4.3 vs. 2.0 ± 1.0; p < .05) and significantly greater time-point symptom load than KME drinks 1-2 hr postdrink.

    PMID 31034254 · one of two readings recorded this

  • gastrointestinal symptom load, symptom type and severity rated 0 to 8 on a Likert scale

    increases, 13.8 ± 4.3 vs. 2.0 ± 1.0 (high-dose vs low-dose ketone salt)

    Not recorded as a finding: the comparison was against another active treatment

    High-dose KS drinks caused greater total-visit symptom load than low-dose KS drinks (13.8 ± 4.3 vs. 2.0 ± 1.0; p < .05) and significantly greater time-point symptom load than KME drinks 1-2 hr postdrink.

    PMID 31034254 · one of two readings recorded this

  • Total-visit gastrointestinal symptom load

    no effect

    However, during exercise, there was no significant difference in total-visit symptom load between KME+CHO (4.2 ± 1.0) and CHO (7.2 ± 1.9) drinks

    PMID 31034254 · one of two readings recorded this

  • Total-visit gastrointestinal symptom load

    increases, p = 0.05

    At rest, KME drinks caused greater total-visit symptom load than CHO drinks (5.0 ± 1.6 vs. 0.6 ± 0.4; p < .05)

    PMID 31034254 · one of two readings recorded this

  • Total-visit gastrointestinal symptom load

    increases, p = 0.05

    High-dose KS drinks caused greater total-visit symptom load than low-dose KS drinks (13.8 ± 4.3 vs. 2.0 ± 1.0; p < .05)

    PMID 31034254 · one of two readings recorded this

  • Visits with no symptoms reported after ketone drinks

    n = 60

    The number of visits with no symptoms reported after ketone drinks was n = 32/60 in Study 1, n = 9/32 in Study 2, and n = 20/42 in Study 3

    PMID 31034254 · one of two readings recorded this

  • Visits with no symptoms reported after ketone drinks

    n = 32

    The number of visits with no symptoms reported after ketone drinks was n = 32/60 in Study 1, n = 9/32 in Study 2, and n = 20/42 in Study 3

    PMID 31034254 · one of two readings recorded this

  • Visits with no symptoms reported after ketone drinks

    n = 42

    The number of visits with no symptoms reported after ketone drinks was n = 32/60 in Study 1, n = 9/32 in Study 2, and n = 20/42 in Study 3

    PMID 31034254 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.0001

    baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.0001

    baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.0001

    baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.001

    baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus baseline

    increases, p = 0.0001

    baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0001

    compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0001

    compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.0001

    compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.01

    compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate versus control

    increases, p = 0.001

    compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate

    increases

    KE (group 2) | 0.79 ± 0.029 | 1.76 ± 0.087 | ****/14.550 | ****/13.610

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate

    increases

    KEKS (group 5) | 0.83 ± 0.041 | 1.55 ± 0.073 | ****/11.340 | ****/10.400

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate

    increases

    KEMCT (group 6) | 0.80 ± 0.033 | 2.14 ± 0.172 | ****/20.230 | ****/19.280

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate

    increases

    KS (group 3) | 0.83 ± 0.031 | 1.25 ± 0.033 | ***/6.805 | **/5.860

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate

    increases

    KSMCT (group 4) | 0.81 ± 0.023 | 1.33 ± 0.049 | ****/7.939 | ***/6.994

    PMID 32000673 · one of two readings recorded this

  • blood beta-hydroxybutyrate

    no effect

    SD (control; group 1) | 0.80 ± 0.037 | 0.86 ± 0.018 | −/0.945 | –

    PMID 32000673 · one of two readings recorded this

  • blood glucose and body weight change after treatment

    no effect

    After the 7th treatment day, changes in glucose levels and body weight of animals were not detected

    PMID 32000673 · one of two readings recorded this

  • blood glucose

    no effect

    KE (group 2) | 91.50 ± 2.284 | 97.63 ± 4.342 | −/2.386 | −/0.623

    PMID 32000673 · one of two readings recorded this

  • blood glucose

    no effect

    KEKS (group 5) | 86.38 ± 2.398 | 92.13 ± 3.388 | −/0.865 | −/0.899

    PMID 32000673 · one of two readings recorded this

  • blood glucose

    no effect

    KEMCT (group 6) | 85.00 ± 2.659 | 80.88 ± 4.286 | −/2.248 | −/4.011

    PMID 32000673 · one of two readings recorded this

  • blood glucose

    no effect

    KS (group 3) | 88.38 ± 1.772 | 100.13 ± 5.482 | −/3.078 | −/1.314

    PMID 32000673 · one of two readings recorded this

  • blood glucose

    no effect

    KSMCT (group 4) | 83.63 ± 3.600 | 97.00 ± 5.745 | −/2.213 | −/0.449

    PMID 32000673 · one of two readings recorded this

  • blood glucose

    no effect

    SD (control; group 1) | 89.00 ± 1.937 | 95.38 ± 2.672 | −/1.764 | –

    PMID 32000673 · one of two readings recorded this

  • body weight

    no effect

    KE (group 2) | 331.9 ± 2.496 | 324.9 ± 2.608 | −/0.027

    PMID 32000673 · one of two readings recorded this

  • body weight

    no effect

    KEKS (group 5) | 316.9 ± 5.377 | 306.6 ± 6.434 | −/3.986

    PMID 32000673 · one of two readings recorded this

  • body weight

    no effect

    KEMCT (group 6) | 321.8 ± 5.502 | 316.8 ± 5.640 | −/1.790

    PMID 32000673 · one of two readings recorded this

  • body weight

    no effect

    KS (group 3) | 323.1 ± 2.394 | 313.5 ± 3.942 | −/2.495

    PMID 32000673 · one of two readings recorded this

  • body weight

    no effect

    KSMCT (group 4) | 318.0 ± 5.119 | 314.0 ± 5.719 | −/2.386

    PMID 32000673 · one of two readings recorded this

  • body weight

    no effect

    SD (control, group 1) | 325.0 ± 3.134 | 331.8 ± 4.427 | −/1.464

    PMID 32000673 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases

    or the group means were considered (R2 = 0.5553)

    PMID 32000673 · one of two readings recorded this

  • correlation of latency to immobility with blood beta-hydroxybutyrate

    increases

    when individual data points (R2 = 0.2933)

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    no effect

    DPCPX (group 7) | 146.25 ± 4.443 | −/0.765

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    increases

    KE (group 2) | 173.50 ± 3.105 | ****/10.220

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    increases

    KEKS (group 5) | 183.88 ± 4.299 | ****/13.680

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    increases

    KEMCT (group 6) | 171.75 ± 2.226 | ****/9.634

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    increases

    KS (group 3) | 162.50 ± 1.679 | ***/6.548

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    increases

    KSMCT (group 4) | 157.88 ± 3.446 | */5.005

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    no effect

    SCH 58261 (group 8) | 141.63 ± 4.935 | −/0.283

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    no effect

    KEKS + DPCPX (group 9) | 138.13 ± 4.202 | −/1.177

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    increases

    KEKS + SCH 58261 (group 10) | 187.13 ± 5.531 | ****/12.290

    PMID 32000673 · one of two readings recorded this

  • latency to immobility under isoflurane

    SD (control, group 1) | 142.88 ± 2.474 | –

    PMID 32000673 · one of two readings recorded this

  • latency to immobility versus control

    increases, p = 0.0001

    compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • latency to immobility versus control

    increases, p = 0.0001

    compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • latency to immobility versus control

    increases, p = 0.0001

    compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • latency to immobility versus control

    increases, p = 0.001

    compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • latency to immobility versus control

    increases, p = 0.05

    compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)

    PMID 32000673 · one of two readings recorded this

  • latency to immobility versus control

    increases, p = 0.0001

    both the rate of this increase and its significance level (p < 0.0001)

    PMID 32000673 · one of two readings recorded this

  • latency to isoflurane-induced immobility, seconds from chamber closure

    increases, p < 0.001 for KS against control

    Not recorded as a finding: no outcome node for anaesthetic induction latency

    Treatments by all exogenous ketone supplements (KE, KS, KSMCT, KEKS and KEMCT; group 2–6) caused a significant increase in the number of seconds required before anesthetic induction (the time until immobility), compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT) (Table 3) on the 7th day of treatment.

    PMID 32000673 · one of two readings recorded this

  • acute blood ketone response to a single dose, post-treatment

    increases, p = 0.001

    Post-Treatment = +0.4 ± 0.4 mmol/L; p < 0.001

    PMID 33111587 · one of two readings recorded this

  • acute blood ketone response to a single dose, pre-treatment

    increases, p = 0.001

    Pretreatment = +0.4 ± 0.3 mmol/L; p < 0.001

    PMID 33111587 · one of two readings recorded this

  • acute blood ketone response to a single dose

    no effect

    At pre- and post-treatment, CON showed no acute changes in blood ketones after a single-dosing

    PMID 33111587 · one of two readings recorded this

  • acute single-dose blood ketone response, pre versus post treatment

    no effect

    These acute single-dosing responses in blood ketone levels for KET did not change between pre- and post-treatment

    PMID 33111587 · one of two readings recorded this

  • average time-to-completion of two 800 m time trials (TTAVG)

    no effect

    KET demonstrated a faster TTAVG from pre- to post-treatment (-6.1 ± 8.9 s; p = 0.02) while CON showed no change

    PMID 33111587 · one of two readings recorded this

The whole record — 535 rows